Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.

Vivek Subbiah Sant P Chawla Anthony P Conley Breelyn A Wilky Anthony W Tolcher Nehal J Lakhani David Berz Vasily Andrianov William Crago Monica Holcomb Abrahim Hussain Carson Veldstra James Kalabus Brianne O'Neill Lane Senne Emily Rowell Analeah B Heidt Katelyn M Willis Brendan P Eckelman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

INBRX-109 demonstrated encouraging antitumor activity with a favorable safety profile in patients with unresectable/metastatic chondrosarcoma. A randomized, placebo-controlled, phase 2 trial (ChonDRAgon, NCT04950075) will further evaluate INBRX-109 in conventional chondrosarcoma.

Keyphrases

placebo controlled
small cell lung cancer
squamous cell carcinoma
double blind
monoclonal antibody
study protocol
randomized controlled trial
locally advanced
clinical trial
cell therapy
radiation therapy
phase ii
open label
liver metastases